245 related articles for article (PubMed ID: 22538974)
1. Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.
Ali HR; Dawson SJ; Blows FM; Provenzano E; Pharoah PD; Caldas C
Br J Cancer; 2012 May; 106(11):1798-806. PubMed ID: 22538974
[TBL] [Abstract][Full Text] [Related]
2. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
[TBL] [Abstract][Full Text] [Related]
3. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
[TBL] [Abstract][Full Text] [Related]
4. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.
Tökés AM; Szász AM; Geszti F; Lukács LV; Kenessey I; Turányi E; Meggyesházi N; Molnár IA; Fillinger J; Soltész I; Bálint K; Hanzély Z; Arató G; Szendröi M; Kulka J
J Clin Pathol; 2015 Apr; 68(4):274-82. PubMed ID: 25595275
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
7. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer.
Yamamoto S; Yamamoto-Ibusuki M; Yamamoto Y; Fujiwara S; Iwase H
BMC Cancer; 2013 Apr; 13():217. PubMed ID: 23627634
[TBL] [Abstract][Full Text] [Related]
9. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.
Millar EK; Graham PH; McNeil CM; Browne L; O'Toole SA; Boulghourjian A; Kearsley JH; Papadatos G; Delaney G; Fox C; Nasser E; Capp A; Sutherland RL
Br J Cancer; 2011 Jul; 105(2):272-80. PubMed ID: 21712826
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.
Klintman M; Bendahl PO; Grabau D; Lövgren K; Malmström P; Fernö M;
Mod Pathol; 2010 Feb; 23(2):251-9. PubMed ID: 19935641
[TBL] [Abstract][Full Text] [Related]
12. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
13. The potential utility of geminin as a predictive biomarker in breast cancer.
Sundara Rajan S; Hanby AM; Horgan K; Thygesen HH; Speirs V
Breast Cancer Res Treat; 2014 Jan; 143(1):91-8. PubMed ID: 24292956
[TBL] [Abstract][Full Text] [Related]
14. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
15. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
17. Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis.
Liang X; Wang D; Wang Y; Zhou Z; Zhang J; Li J
Diagn Pathol; 2012 Jul; 7():84. PubMed ID: 22809428
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer in young women and prognosis: How important are proliferation markers?
Fredholm H; Magnusson K; Lindström LS; Tobin NP; Lindman H; Bergh J; Holmberg L; Pontén F; Frisell J; Fredriksson I
Eur J Cancer; 2017 Oct; 84():278-289. PubMed ID: 28844016
[TBL] [Abstract][Full Text] [Related]
19. Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma.
Ramani P; Nash R; Rogers CA
Histopathology; 2015 Feb; 66(3):370-9. PubMed ID: 25297850
[TBL] [Abstract][Full Text] [Related]
20. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
